21 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
and biotech industries.
Engaged Merit Cudkowicz, MD, MSc as expert clinical advisor.
Dr. Cudkowicz is a world-renowned neurologist who has dedicated her
8-K
EX-99.1
COYA
Coya Therapeutics Inc
8 Aug 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
7:05am
Cudkowicz, MD, MSc as expert clinical advisor and Dr. Guillaume Dorothée, Ph.D., to the Company’s Scientific Advisory Board.
“We had a strong quarter
DEF 14A
COYA
Coya Therapeutics Inc
19 May 23
Definitive proxy
4:31pm
spectrum disorder. Prior to Roche, between 2011 and 2013, Dr. Garren held the role of Executive Director, Translational Medicine Expert in Neuroscience … determined that Dr. Dov Goldstein qualifies as an audit committee financial expert within the meaning of SEC regulations and The Nasdaq Marketplace Rules. Our
10-K
EX-3.2
7ujb8t91q
29 Mar 23
Annual report
4:08pm
424B4
5t90 rxil
30 Dec 22
Prospectus supplement with pricing info
4:17pm
S-1/A
dmzx9x
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
EX-10.7
ntjy4mrdj63j3vf
5 Dec 22
IPO registration (amended)
8:16am
S-1
EX-10.7
mr1wgvm7
18 Nov 22
IPO registration
5:06pm
S-1
x2axwcwa
18 Nov 22
IPO registration
5:06pm
S-1
EX-10.2
ppfwkxfo
18 Nov 22
IPO registration
5:06pm
S-1
EX-3.4
dq34zs93064rx9f
18 Nov 22
IPO registration
5:06pm
DRS/A
EX-3
i4sx09 1iil0f3fta
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
qllbbcehhjb6 1e6
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
EX-10
s7q78 j20k2j3
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
e31qfbxnsx1kxskmvw
7 Oct 22
Draft registration statement (amended)
12:00am